Cancer Epidemiology最新文献

{"title":"A national study of lung cancer patients below 50 years: Variations in characteristics and outcomes by age","authors":"Katrine Kristensen ,&nbsp;Anja Gouliaev ,&nbsp;Torben Riis Rasmussen ,&nbsp;Niels Lyhne Christensen","doi":"10.1016/j.canep.2025.102949","DOIUrl":"10.1016/j.canep.2025.102949","url":null,"abstract":"<div><h3>Background</h3><div>Lung cancer predominantly affects the elderly. However, a small yet significant subgroup of patients below fifty years presents unique challenges in diagnosis and treatment. This study aims to describe the characteristics and outcomes of these young patients, emphasizing the need for improved diagnostic strategies and better prognostic outcomes.</div></div><div><h3>Method</h3><div>This national cohort study includes all patients diagnosed 2012–2023 recorded in the Danish Lung Cancer Registry. Patients below fifty years at diagnosis were categorized as young.</div></div><div><h3>Results</h3><div>Out of 57,325 patients a total of 1312 (2.3 %) were below fifty years at diagnosis. Young patients were more likely to be female (p = 0.006), diagnosed with adenocarcinoma (p &lt; 0.001) and ten times more frequent anaplastic lymphoma kinase (ALK) mutated (p &lt; 0.001). Young patients had fewer packyears (p &lt; 0.001), better performance status (p &lt; 0.001), lower Charlson Comorbidity index (p &lt; 0.001), but were more frequently diagnosed in incurable disease stage, (68.0 % vs. 60.9 % p &lt; 0.001). Adjusted OR of being diagnosed in a curable stage was 0.75 (95 %CI 0.66–0.85) for young patients, while adjusted OR for undergoing treatment with curative intent was 1.88 (1.58–2.23). Kaplan-Meier analysis indicated higher survival rates for young patients across all stages, but only marginally in stages IIIB-IV.</div></div><div><h3>Conclusion</h3><div>Young patients diagnosed with lung cancer are less likely to be diagnosed in a curable stage. The pathology and smoking habits differ significantly from patients above fifty years. While pending screening is important for the older population of smokers, it remains essential to consistently address the need for early diagnosis in the young population to prevent exacerbating existing disparities.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102949"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145424764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends and characteristics of early-onset colorectal cancer in the state of Florida, 2002–2021","authors":"Young-Rock Hong ,&nbsp;Lee Revere ,&nbsp;Kathryn M. Ross ,&nbsp;Peihua Qiu ,&nbsp;Mattia Prosperi ,&nbsp;Thomas J. George ,&nbsp;Beth A. Virnig","doi":"10.1016/j.canep.2025.102932","DOIUrl":"10.1016/j.canep.2025.102932","url":null,"abstract":"<div><h3>Background</h3><div>Early-onset colorectal cancer (EOCRC), defined as diagnosis before age 50, is a growing public health concern. Despite increasing national incidence among younger adults, state-specific analyses for Florida remain limited. Florida's large and demographically unique population necessitates investigation into EOCRC trends and patient characteristics.</div></div><div><h3>Methods</h3><div>This population-based study utilized colorectal cancer incidence data for Florida residents aged 25–49 diagnosed between 2002 and 2021, from the Florida Cancer Data System and National Program of Cancer Registries. Joinpoint regression evaluated age-adjusted incidence trends across demographic and clinical factors. Age-period-cohort analysis explored generational effects, while multivariate logistic regression identified factors associated with advanced-stage diagnosis (regional or distant).</div></div><div><h3>Results</h3><div>Among 16,318 EOCRC cases identified during 2002–2021, overall incidence increased significantly (AAPC=1.48 %, P &lt; .001), driven primarily by colon cancers (AAPC=1.53 %, P &lt; .001), while rectal cancers showed non-significant increase (AAPC=0.53 %, P = 0.185). A concerning shift toward advanced stages at diagnosis emerged (P &lt; 0.001), with localized disease decreasing from 32.8 % to 26.2 %, while regional (34.6–41.0 %) and distant metastases (21.9–26.8 %) increased substantially. This stage migration was confirmed by significant increases in regional (AAPC=2.10 %, P &lt; .001) and distant disease (AAPC=2.71 %, P &lt; .001) incidence. Strong birth cohort effects, indicating increasing risk with rate ratios exceeding 2.0 for recent cohorts, were evident predominantly in non-Hispanic White individuals. Conversely, Hispanic and non-Hispanic Black patients showed no significant cohort effects but consistently presented with higher odds of advanced-stage disease compared to non-Hispanic Whites (AOR=1.13 and AOR=1.11, respectively). Uninsured (AOR=1.23) and Medicaid-covered patients (AOR=1.52) faced significantly higher odds of advanced presentation compared to privately insured individuals.</div></div><div><h3>Conclusion</h3><div>Florida experienced sustained EOCRC incidence increases from 2002 to 2021, accompanied by advanced-stage diagnosis increases and notable disparities. Birth cohort effects primarily drove increased risk in non-Hispanic White populations, while barriers to timely care, including insurance status, likely contributed to delayed diagnoses in minority communities, underscoring urgent needs for targeted interventions.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102932"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145050139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hospital-based gallbladder cancer registry from a high-volume referral cancer centre in India: Insights into epidemiology and roadmap for enhancing cancer care","authors":"Shraddha Patkar ,&nbsp;Tanvi M. Shah ,&nbsp;Gurudutt Varty ,&nbsp;Abdeali Saif A. Kaderi ,&nbsp;Vishnu Menon ,&nbsp;D. Baskaran ,&nbsp;Vikas Ostwal ,&nbsp;Anant Ramaswamy ,&nbsp;Mukta Ramadwar ,&nbsp;Rajesh Dikshit ,&nbsp;Mahesh Goel","doi":"10.1016/j.canep.2025.102958","DOIUrl":"10.1016/j.canep.2025.102958","url":null,"abstract":"<div><h3>Purpose</h3><div>Gallbladder cancer (GBC) is a significant public health concern in India, with a high disease burden and complex challenges in delivering effective care. This registry aims to shed light on the epidemiology, and barriers to early detection and treatment, to inform future research and policy initiatives.</div></div><div><h3>Methods</h3><div>From January 2019 to December 2022, all consecutive patients with a presumed diagnosis of GBC, presenting to our institution were prospectively enrolled after informed consent. Each patient completed a standardized questionnaire, and clinical, radiologic and treatment data were recorded in a case record form. Management followed standard institutional protocols. Survival analysis was done using Kaplan–Meier curves.</div></div><div><h3>Results</h3><div>A total of 1950 patients were included, 1441 (73.9 %) of these hailed from the Gangetic belt region (northern and eastern states); an additional 209 (10.7 %) were migrants from these regions, representing 84.6 % of the cohort. Over 55 % belonged to lower socioeconomic classes. At presentation, 60 % had metastatic disease; only 318 (16.3 %) were eligible for curative-intent therapy, and 132 (6.8 %) did not complete planned treatment. Treatment dropout correlated significantly with male gender (p = 0.012) and unemployment (p = 0.014). After a median follow-up of 38.2 months, median overall survival was 58.2 months for early-stage patients versus 4.2 months for those with metastatic disease.</div></div><div><h3>Conclusion</h3><div>This registry is an attempt to generate evidence-based awareness about the substantial disease burden of gallbladder cancers in India and highlights the un-met need for capacity building of our health system, in order to provide, timely, accessible and cost-effective management of this disease.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102958"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145524878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementation barriers to lung cancer screening: Conceptual misconceptions and the importance of seeking synergy with smoking cessation","authors":"Arn Migowski","doi":"10.1016/j.canep.2025.102957","DOIUrl":"10.1016/j.canep.2025.102957","url":null,"abstract":"","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102957"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145497557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systematic review on the risk of developing cancer and frequency of alcohol consumption behaviors in US adults","authors":"Isabella Abraham ,&nbsp;Gabriella Dasilva ,&nbsp;Kayla Ernst ,&nbsp;Alexandra Campson ,&nbsp;Alana Starr ,&nbsp;Christine Kamm ,&nbsp;George Kosseifi ,&nbsp;Morgan Decker ,&nbsp;Sahar Kaleem ,&nbsp;Nada Eldawy ,&nbsp;Paige Brinzo ,&nbsp;Tiffany Follin ,&nbsp;Christine Ramdin ,&nbsp;Maria Mejia ,&nbsp;Lewis S. Nelson ,&nbsp;Lea Sacca","doi":"10.1016/j.canep.2025.102956","DOIUrl":"10.1016/j.canep.2025.102956","url":null,"abstract":"<div><h3>Background</h3><div>The frequency and quantity of alcohol consumption, even at moderate levels, influence both cancer incidence and outcomes. This systematic review examines the relationship between varying levels of alcohol consumption and the risk of developing cancer in U.S. adults. It also explores the comorbid conditions that may increase long-term cancer risk among alcohol users and identifies the social and demographic factors that place certain population groups at heightened risk.</div></div><div><h3>Methods</h3><div>The review followed the Arksey &amp; O’Malley Framework and the Joanna Briggs Institute (JBI) recommendations for the extraction, analysis, and presentation of results in systematic reviews. [This framework consists of five steps: (1) identify research questions; (2) search for relevant studies; (3) select studies relevant to the research questions; (4) chart the data; and (5) collate, summarize, and report results.</div></div><div><h3>Results</h3><div>A total of 62 studies were retained for analysis following title, abstract, and full text screening. Race/ethnicity (n = 46/62) and age (n = 42/62) were the most frequently mentioned individual risk factors. Across the 62 studies reviewed, alcohol consumption was consistently identified as a risk factor for several types of cancer, including breast (n = 23/62), colorectal (n = 13/62), and liver (n = 10/62), among others. Other alcohol-associated comorbidities reported include obesity (n = 8/62), alcoholic liver disease (n = 5/62), and diabetes (n = 4/62).</div></div><div><h3>Conclusion</h3><div>Alcohol intake, particularly at higher frequency or greater quantity, was consistently associated with elevated risk for multiple cancers, most notably colorectal, breast, and liver. Dose-response relationships were a common finding, underscoring that risk is not limited to heavy or chronic use.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102956"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145524874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal trends in AML incidence and mortality, with a focus on AML-related deaths among patients with myelodysplastic syndromes in the United States, 1999–2023","authors":"Natalie A. Akoto ,&nbsp;Albert E. Orhin ,&nbsp;Denise Eke Chukwu ,&nbsp;Albert Gyato ,&nbsp;Simon Egyin ,&nbsp;Maame Yaa Idun ,&nbsp;Kwabena Owusu Aninkora","doi":"10.1016/j.canep.2025.102960","DOIUrl":"10.1016/j.canep.2025.102960","url":null,"abstract":"<div><h3>Background</h3><div>Myelodysplastic syndromes (MDS) are bone marrow disorders that often affect older adults and can lead to acute myeloid leukemia (AML), a more aggressive cancer. While this progression is well known, national trends in AML-related deaths, specifically among patients with MDS, have not been well described.</div></div><div><h3>Methods</h3><div>Using CDC WONDER death certificate data from 1999 to 2023, we identified adults aged 25 years and above who died from AML with MDS listed as a contributing cause. We analyzed demographics, place of death, and trends over time. Age-adjusted mortality rates were calculated and stratified by sex, race, geography, and urbanization. We also examined national trends in AML incidence and mortality-to-incidence ratios (MIR).</div></div><div><h3>Results</h3><div>AML incidence was 5.8 per 100,000, rising slightly over time (AAPC + 0.5 %; 95 % CI: 0.25–0.70). Among 16,979 AML-related deaths in people with MDS, most were male (61.6 %), White (91.8 %), and aged ≥ 75 years. Nearly half died in hospitals, while &lt; 1 % underwent autopsies. The age-adjusted mortality rate was 0.5 per 100,000 in males and 0.2 in females (p &lt; 0.0001). Mortality declined overall (AAPC − 1.16 %; 95 % CI: − 1.75 to − 0.57), with the sharpest drop between 2021 and 2023 (APC − 17.12 %, 95 % CI: − 22.61 to − 9.20). Improvements were most notable in urban areas and among White patients.</div></div><div><h3>Conclusion</h3><div>AML-related mortality in MDS patients has declined over the past 25 years, likely reflecting progress in treatment and supportive care. However, disparities persist. More equitable access to advanced therapies is needed to ensure all patients benefit from recent advances.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102960"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145524955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Human Papillomavirus in Arica and Antofagasta, in the north of Chile","authors":"María Jesús Acuña ,&nbsp;Edgardo Mancilla ,&nbsp;Dania Acuña ,&nbsp;Giuliano Bernal","doi":"10.1016/j.canep.2025.102913","DOIUrl":"10.1016/j.canep.2025.102913","url":null,"abstract":"<div><h3>Background</h3><div>Cervical cancer is primarily caused by the Human Papillomavirus (HPV). Despite all the advances in early detection of HPV infection, cervical cancer remains one of the most common types of cancer in women, with a high presence in Latin America. We previously reported on the prevalence of HPV in the Coquimbo region, so the objective of this study was to determine the frequency of HPV in women in the Antofagasta and Arica regions of northern Chile.</div></div><div><h3>Methods</h3><div>We analyzed 823 cervical samples from women aged 15–79 who attended gynecological checkups during 2024 to detect HPV genotypes using qPCR. Of these, 199 come from Arica and 624 from Antofagasta, in northern Chile.</div></div><div><h3>Results</h3><div>The overall HPV positivity rate was 19.20 %; 23.62 % in Arica and 17.79 % in Antofagasta. The HR-HPV positivity rates in the G1 (15–29 years) and G2 (30–79 years) age groups were 30.92 % and 16.54 %, respectively. The most prevalent genotypes of HPV infection among our entire population were HPV16, HPV 31, and HPV52. Single infection (75.95 %) was the main HPV infection pattern observed in the entire group, followed by double or multiple infection (24.05 %), which was similar in Groups 1 and 2, where the prevalence of single infection was 72.34 % and 77.48 %, respectively.</div></div><div><h3>Conclusion</h3><div>The prevalence of HPV infections in women in the Arica and Antofagasta regions appears lower than that previously reported for Coquimbo, but similar to that reported in Chile by the Ministry of Health. This reflects the great heterogeneity of HPV prevalence in our vast country. On the other hand, molecular detection of 14 HR-HPV genotypes is important because it will not only help women avoid cervical cancer, but could also inform the introduction of new vaccines targeting a broader spectrum of HR-HPV.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102913"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145004392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term air pollution exposure and mortality outcomes in colorectal cancer patients: Evidence from a multicenter longitudinal study","authors":"Chih-Wen Wang ,&nbsp;Pinpin Lin ,&nbsp;Yu-Cheng Chen ,&nbsp;Yueh-Hsia Luo ,&nbsp;Chih-Da Wu ,&nbsp;Ching-Chun Li ,&nbsp;Chun-Hung Richard Lin","doi":"10.1016/j.canep.2025.102948","DOIUrl":"10.1016/j.canep.2025.102948","url":null,"abstract":"<div><h3>Background</h3><div>Limited evidence exists regarding the relationship between air pollution and all-cause mortality in colorectal cancer stratified by clinical stages.</div></div><div><h3>Methods</h3><div>In this retrospective cohort study, initiated in 2010, we included patients with pathologically confirmed colorectal carcinoma. Each participant's address was geocoded to the corresponding village/borough or township, for accurate matching with estimated air pollution concentrations. The risk of all-cause mortality was assessed using Kaplan–Meier analysis and Cox proportional hazards regression models.</div></div><div><h3>Results</h3><div>Our study enrolled 5126 colorectal cancer patients, with a median survival time of 72.0 months. Higher exposures were associated with greater all-cause mortality: PM_2.5₅ tertile 3 vs tertile 1—HR 1.32 (95 % CI 1.14–1.52) and SO₂ tertile 3 vs tertile 1—HR 1.22 (95 % CI 1.06–1.40). Stage-stratified results showed PM_2.5 remained significant in stages 0–I (HR 1.62, 95 % CI 1.01–2.58) and III (HR 1.39, 95 % CI 1.11–1.73), whereas SO₂ was significant in stages II (HR 1.62, 95 % CI 1.03–2.53) and III (HR 1.34, 95 % CI 1.07–1.67). In multiplicative interactions, each unit increase in PM_2.5 was linked to a 1 % higher hazard (HR = 1.01; 95 % CI, 1.01–1.02), and each unit increase in SO₂ to a 5 % higher hazard (HR = 1.05; 95 % CI, 1.04–1.05). When stage was included additively, the per-unit effects were larger—7 % for PM_2.5 (HR = 1.07; 95 % CI, 1.05–1.10) and 14 % for SO₂ (HR = 1.14; 95 % CI, 1.11–1.17). Overall, pollutant levels and clinical stage jointly heightened all-cause mortality.</div></div><div><h3>Conclusions</h3><div>Elevated PM_2.5 and SO₂ exposures were significantly associated with higher all-cause mortality, with effect sizes varying by stage and generally stronger in stages 0–I and II–III. Clinical stage interacted both associations, and joint exposure–stage categories showed higher risks, underscoring the need to reduce pollution exposure in high-risk patients.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102948"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145362389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of vaccine-induced immunity to hepatitis B in cancer patients: A 13-year analysis in a quaternary oncological center","authors":"Mariana Cavalheiro Magri ,&nbsp;Victória Gonçalves de Paula ,&nbsp;Marina Rossi de Camargo Pinto ,&nbsp;Débora Bignotto Rosane Battaglia ,&nbsp;Rafael de Oliveira ,&nbsp;Gustavo Manoel Ferreira ,&nbsp;Fátima Mitiko Tengan ,&nbsp;Edson Abdala","doi":"10.1016/j.canep.2025.102946","DOIUrl":"10.1016/j.canep.2025.102946","url":null,"abstract":"<div><h3>Background</h3><div>Hepatitis B virus reactivation may occur in cancer patients, leading to liver damage and early discontinuation of treatment. To evaluate vaccine-induced immunity to hepatitis B, this study investigated the prevalence of anti-HBs antibodies from patients with solid tumors or hematological malignancies.</div></div><div><h3>Methods</h3><div>All cancer patients who underwent serological testing for anti-HBs from 2011 to 2023 and had negative anti-HBc results at the Instituto do Cancer do Estado de Sao Paulo, Brazil, were included. The prevalence of vaccine-induced immunity to hepatitis B during those years was assessed by using linear regression. Characteristics associated with presence of anti-HBs and anti-HBs titers (strongly positive: ≥ 100 IU/L; weakly positive: 10–99 IU/L) were evaluated by using multivariable logistic regression.</div></div><div><h3>Results</h3><div>A total of 23,854 patients were evaluated, 17,249 with solid tumors and 5114 with hematological malignancies. The prevalence of vaccine-induced immunity to hepatitis B was 22.1 %, with a significant linear increase over time (p &lt; 0.001). The presence of vaccine-induced immunity to hepatitis B was associated with younger age (OR=7.23, 95 % CI: 6.55–7.98), female sex (OR=1.25, 95 % CI: 1.15–1.36), non-white patients (OR=1.13, 95 % CI: 1.04–1.22), and patients with hematological malignancies (OR=1.16, 95 %CI: 1.07–1.27). Additionally, the variables younger age (OR=1.64, 95 % CI: 1.39–1.94) and female sex (OR=1.39, 95 % CI: 1.20–1.60) were associated with strongly protective anti-HBs titers (≥ 100 IU/L).</div></div><div><h3>Conclusions</h3><div>This finding indicates that approximately one-quarter of a large population with cancer was protected against HBV infection through serological evidence of anti-HBs. Preventive strategies are needed for cancer patients, who may benefit from hepatitis B vaccination.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102946"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145362390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global burden and international trends of laryngeal cancer incidence: A population-based study of recorded data and national estimates","authors":"Amanda Ramos da Cunha ,&nbsp;Harriet Rumgay ,&nbsp;Jerome Vignat ,&nbsp;Mathieu Laversanne ,&nbsp;Murielle Colombet ,&nbsp;Maria Paula Curado ,&nbsp;Gail Garvey ,&nbsp;Sarbani Ghosh-Laskar ,&nbsp;Brian O’Sullivan ,&nbsp;Shama Virani ,&nbsp;Isabelle Soerjomataram ,&nbsp;Marion Piñeros","doi":"10.1016/j.canep.2025.102935","DOIUrl":"10.1016/j.canep.2025.102935","url":null,"abstract":"<div><div>Laryngeal cancer shows considerable variation in global incidence, which has primarily been studied through national estimates. This study aims to analyse the global incidence of laryngeal cancer, comparing estimated and high-quality recorded data, and examine temporal trends to inform targeted prevention strategies. Estimated incidence rates for 2022 were obtained from the GLOBOCAN 2022 database for 185 countries. Recorded incidence data from population-based cancer registries (PBCRs) for the five-years period 2013–2017 were sourced from Cancer Incidence in Five Continents (CI5-XII). Temporal trends and the Estimated Annual Percent Change were assessed for 34 countries using the Global Cancer Observatory – Cancer Over Time database. The highest estimated age-standardized incidence rates (ASIRs) were observed in Cuba, Moldova, and Romania, particularly among males: 14.8, 12.2, and 10.3 per 100,000, respectively. Recorded data showed significant regional variability, with the highest ASIRs for males in Pskov, Russia (13.3 per 100,000) and the Azores, Portugal (11.8 per 100,000). Most countries exhibited a decline in laryngeal cancer rates among males, while trends among females remained largely stable. Our findings underscore the importance of PBCRs in identifying high-risk populations for developing laryngeal cancer. While national estimates are essential for understanding the global distribution of laryngeal cancer and other malignancies, they may overlook subnational variations. Expanding the coverage and quality of PBCRs is crucial for improving cancer surveillance and enhancing prevention and control efforts at national and global level.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102935"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145152087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}